Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci.


Journal

Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162

Informations de publication

Date de publication:
10 01 2019
Historique:
received: 16 04 2018
pubmed: 26 10 2018
medline: 7 1 2020
entrez: 26 10 2018
Statut: ppublish

Résumé

Few studies have investigated the blood proteome of inflammatory bowel disease (IBD). We characterized the serum abundance of proteins encoded at 163 known IBD risk loci and tested these proteins for their biomarker discovery potential. Based on the Human Protein Atlas (HPA) antibody availability, 218 proteins from genes mapping at 163 IBD risk loci were selected. Targeted serum protein profiles from 49 Crohn's disease (CD) patients, 51 ulcerative colitis (UC) patients, and 50 sex- and age-matched healthy individuals were obtained using multiplexed antibody suspension bead array assays. Differences in relative serum abundance levels between disease groups and controls were examined. Replication was attempted for CD-UC comparisons (including disease subtypes) by including 64 additional patients (33 CD and 31 UC). Antibodies targeting a potentially novel risk protein were validated by paired antibodies, Western blot, immuno-capture mass spectrometry, and epitope mapping. By univariate analysis, 13 proteins mostly related to neutrophil, T-cell, and B-cell activation and function were differentially expressed in IBD patients vs healthy controls, 3 in CD patients vs healthy controls and 2 in UC patients vs healthy controls (q < 0.01). Multivariate analyses further differentiated disease groups from healthy controls and CD subtypes from UC (P < 0.05). Extended characterization of an antibody targeting a novel, discriminative serum marker, the laccase (multicopper oxidoreductase) domain containing 1 (LACC1) protein, provided evidence for antibody on-target specificity. Using affinity proteomics, we identified a set of IBD-associated serum proteins encoded at IBD risk loci. These candidate proteins hold the potential to be exploited as diagnostic biomarkers of IBD.

Sections du résumé

Background
Few studies have investigated the blood proteome of inflammatory bowel disease (IBD). We characterized the serum abundance of proteins encoded at 163 known IBD risk loci and tested these proteins for their biomarker discovery potential.
Methods
Based on the Human Protein Atlas (HPA) antibody availability, 218 proteins from genes mapping at 163 IBD risk loci were selected. Targeted serum protein profiles from 49 Crohn's disease (CD) patients, 51 ulcerative colitis (UC) patients, and 50 sex- and age-matched healthy individuals were obtained using multiplexed antibody suspension bead array assays. Differences in relative serum abundance levels between disease groups and controls were examined. Replication was attempted for CD-UC comparisons (including disease subtypes) by including 64 additional patients (33 CD and 31 UC). Antibodies targeting a potentially novel risk protein were validated by paired antibodies, Western blot, immuno-capture mass spectrometry, and epitope mapping.
Results
By univariate analysis, 13 proteins mostly related to neutrophil, T-cell, and B-cell activation and function were differentially expressed in IBD patients vs healthy controls, 3 in CD patients vs healthy controls and 2 in UC patients vs healthy controls (q < 0.01). Multivariate analyses further differentiated disease groups from healthy controls and CD subtypes from UC (P < 0.05). Extended characterization of an antibody targeting a novel, discriminative serum marker, the laccase (multicopper oxidoreductase) domain containing 1 (LACC1) protein, provided evidence for antibody on-target specificity.
Conclusions
Using affinity proteomics, we identified a set of IBD-associated serum proteins encoded at IBD risk loci. These candidate proteins hold the potential to be exploited as diagnostic biomarkers of IBD.

Identifiants

pubmed: 30358838
pii: 5144272
doi: 10.1093/ibd/izy326
pmc: PMC6327232
doi:

Substances chimiques

Biomarkers 0
Blood Proteins 0
Proteome 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

306-316

Références

PLoS One. 2015 Mar 13;10(3):e0118627
pubmed: 25769033
Lancet. 2016 Jan 9;387(10014):156-67
pubmed: 26490195
Nat Biotechnol. 2010 Dec;28(12):1248-50
pubmed: 21139605
Int J Mol Sci. 2012;13(7):8338-52
pubmed: 22942706
Genes Immun. 2014 Dec;15(8):521-7
pubmed: 25142031
Neuropeptides. 2000 Dec;34(6):338-47
pubmed: 11162290
J Biol Chem. 2007 Sep 14;282(37):27181-91
pubmed: 17640867
Can J Gastroenterol. 2005 Sep;19 Suppl A:5A-36A
pubmed: 16151544
J Proteome Res. 2016 Oct 7;15(10):3473-3480
pubmed: 27570895
PLoS One. 2013 Jun 25;8(6):e67142
pubmed: 23825635
J Immunol. 1985 Nov;135(5):3172-7
pubmed: 3930598
Mol Cell Proteomics. 2005 Apr;4(4):384-93
pubmed: 15695805
PLoS Genet. 2017 Jan 27;13(1):e1006565
pubmed: 28129359
Proteome Sci. 2011 Nov 17;9:73
pubmed: 22093360
J Immunol. 2010 Dec 1;185(11):6413-9
pubmed: 21084670
Nature. 2012 Nov 1;491(7422):119-24
pubmed: 23128233
Cell Immunol. 2009;258(2):115-22
pubmed: 19426966
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Genes Immun. 2016 Jun;17(4):261-4
pubmed: 27098602
N Biotechnol. 2016 Sep 25;33(5 Pt A):582-92
pubmed: 26417875
Biochem Pharmacol. 2007 May 1;73(9):1422-33
pubmed: 17258689
Mol Biol Rep. 2012 May;39(5):5659-67
pubmed: 22198550
Mol Cell Proteomics. 2003 Jun;2(6):405-14
pubmed: 12796447
BMC Bioinformatics. 2011 Jun 22;12:253
pubmed: 21693065
J Biomed Sci. 2013 Dec 01;20:87
pubmed: 24289115
J Immunol. 2006 Jun 15;176(12):7354-60
pubmed: 16751379
Scand J Gastroenterol Suppl. 1989;170:2-6; discussion 16-9
pubmed: 2617184
Mol Divers. 2006 May;10(2):169-86
pubmed: 16770514
Methods Mol Biol. 2013;1023:137-45
pubmed: 23765623
Ann Gastroenterol. 2014;27(4):294-303
pubmed: 25331623
Nat Immunol. 2016 Sep;17(9):1046-56
pubmed: 27478939
N Engl J Med. 2009 Dec 31;361(27):2609-18
pubmed: 20018961
Scand J Gastroenterol. 2017 Feb;52(2):125-135
pubmed: 27610713
Front Immunol. 2012 Mar 21;3:57
pubmed: 22566938
Annu Rev Immunol. 2010;28:573-621
pubmed: 20192811
Analyst. 2018 Jul 23;143(15):3526-3539
pubmed: 29947623
Nat Immunol. 2002 Sep;3(9):830-5
pubmed: 12154356
Mol Cell Proteomics. 2016 Jan;15(1):256-65
pubmed: 26530476
Proteomics. 2005 Nov;5(17):4327-37
pubmed: 16237735
PLoS One. 2013 Aug 19;8(8):e72739
pubmed: 23977348
Gastroenterology. 2012 Jan;142(1):46-54.e42; quiz e30
pubmed: 22001864
Inflamm Bowel Dis. 2017 Jan;23(1):158-164
pubmed: 27930409
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809
J Proteome Res. 2014 Nov 7;13(11):4607-19
pubmed: 25231264
Nature. 2011 Jun 15;474(7351):307-17
pubmed: 21677747
Acta Endocrinol (Copenh). 1985 Sep;110(1):135-9
pubmed: 3898693
Arthritis Rheumatol. 2015 Jan;67(1):288-95
pubmed: 25220867

Auteurs

Kimi Drobin (K)

Affinity Proteomics, SciLifeLab, School of Biotechnology, KTH, Royal Institute of Technology, Stockholm, Sweden.

Ghazaleh Assadi (G)

Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.

Mun-Gwan Hong (MG)

Affinity Proteomics, SciLifeLab, School of Biotechnology, KTH, Royal Institute of Technology, Stockholm, Sweden.

Eni Andersson (E)

Affinity Proteomics, SciLifeLab, School of Biotechnology, KTH, Royal Institute of Technology, Stockholm, Sweden.

Claudia Fredolini (C)

Affinity Proteomics, SciLifeLab, School of Biotechnology, KTH, Royal Institute of Technology, Stockholm, Sweden.

Björn Forsström (B)

Affinity Proteomics, SciLifeLab, School of Biotechnology, KTH, Royal Institute of Technology, Stockholm, Sweden.

Anna Reznichenko (A)

Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.

Tahmina Akhter (T)

Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.

Weronica E Ek (WE)

Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.
Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.

Ferdinando Bonfiglio (F)

Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.
Department of Gastrointestinal and Liver Diseases, Biodonostia Health Research Institute, San Sebastián, Spain.

Mark Berner Hansen (MB)

AstraZeneca R&D Mölndal, Innovative and Global Medicines, Mölndal, Sweden.
Digestive Disease Center, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.

Kristian Sandberg (K)

Science for Life Laboratory, Drug Discovery & Development Platform & Organic Pharmaceutical Chemistry, Department of Medicinal Chemistry, Uppsala Biomedical Center, Uppsala University, Uppsala, Sweden.
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Dario Greco (D)

Institute of Biotechnology, University of Helsinki, Helsinki, Finland.

Dirk Repsilber (D)

School of Medical Sciences, Örebro University, Örebro, Sweden.

Jochen M Schwenk (JM)

Affinity Proteomics, SciLifeLab, School of Biotechnology, KTH, Royal Institute of Technology, Stockholm, Sweden.

Mauro D'Amato (M)

Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.
BioDonostia Health Research Institute, San Sebastian and IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.

Jonas Halfvarson (J)

Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH